START:IP Portfolio

Technologies for START:IP 2021

Cell-based test for kinase inhibitors

Many cancers are driven by hyperactive cell signaling proteins, known as kinases. Drugs that inhibit these kinases make attractive anticancer therapies. A bottleneck for kinase inhibitor development is being able to test whether inhibition is effective, for which current testing methods are inadequate. This method directly measures kinase activity in live cells, to better assess potential kinase inhibitors.

Read More »

(Bookmark technologies to show them here)

No Bookmarks

Persönliches Profil